<DOC>
	<DOCNO>NCT01960387</DOCNO>
	<brief_summary>The combination clofarabine cytarabine effective reasonably well-tolerated treatment regimen patient either relapsed/refractory newly diagnose AML . For prospective study , propose use clofarabine cytarabine second course induction therapy patient persistent AML treatment anthracycline cytarabine .</brief_summary>
	<brief_title>Phase II Clofarabine Cytarabine Newly Diagnosed Acute Myeloid Leukemia</brief_title>
	<detailed_description>The primary objective prospective study evaluate efficacy ( i.e. , complete response rate ) clofarabine cytarabine second course therapy treatment AML . The secondary objective assess treatment-related toxicity , determine overall relapse-free survival patient AML treat regimen , evaluate potential factor predictive response . The investigational nature objective study , procedure involve associated risk , potential benefit , potential alternative therapy explain patient , sign informed consent document obtain . Once consent , eligible patient treat acute leukemia service University Pittsburgh Cancer Institute inpatient unit . Prior start chemotherapy , patient receive dexamethasone ondansetron pre-medication . Clofarabine administer intravenous infusion day 1 5 . Patients monitor closely vital sign . Cytarabine give intravenous infusion , start 3 ( maximum 4 ) hour completion clofarabine administration day 1 5 .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Antimetabolites</mesh_term>
	<criteria>1 . Patients newly diagnose AML base World Health Organization classification persistent disease first course treatment anthracycline cytarabine 2 . Able understand ability provide write informed consent 3 . Patients 18 year age 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 5 . Left ventricular ejection fraction ( LVEF ) ≥ 50 % 6 . Negative urine pregnancy test females 7 . All subject must agree use effective method contraception receive study drug 1 . Diagnosis acute promyelocytic leukemia 2 . Relapsed AML 3 . Prior use clofarabine 4 . Previous allogeneic autologous hematopoietic cell transplantation 5 . Impaired liver function ( serum total bilirubin &gt; 2.0 mg/dL , alanine aminotransferase aspartate aminotransferase ≥ 4 x upper limit normal ) 6 . Impaired renal function ( serum creatinine ≥ 2.0 mg/dL ) 7 . Uncontrolled lifethreatening infection respond antimicrobial therapy 8 . History psychiatric disorder may compromise compliance protocol allow appropriate inform consent 9 . Concurrent active malignancy ; exception include patient disease free 5 year , patient history completely resect nonmelanoma skin cancer successfully treat situ carcinoma , patient another malignancy indolent definitively treat 10 . Evidence severe uncontrolled systemic disease ( e.g. , unstable uncompensated respiratory cardiac disease )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>AML</keyword>
	<keyword>clofarabine</keyword>
	<keyword>cytarabine</keyword>
	<keyword>persistent AML</keyword>
	<keyword>induction therapy</keyword>
</DOC>